Šalis: Pietų Afrika
kalba: anglų
Šaltinis: South African Health Products Regulatory Authority (SAHPRA)
Lennon
TRANQIPAM-0,5 mg TABLETS TRANQIPAM-1 mg TABLETS TRANQIPAM-2,5 mg TABLETS SCHEDULING STATUS: S5 PROPRIETARY NAME (and dosage form) TRANQIPAM-0,5 mg TABLETS TRANQIPAM-1 mg TABLETS TRANQIPAM-2,5 mg TABLETS COMPOSITION: Each TRANQIPAM-0,5 mg tablet contains 0,5 mg lorazepam . Each TRANQIPAM-1 mg tablet contains 1 mg lorazepam. Each TRANQIPAM-2,5 mg tablet contains 2,5 mg lorazepam. Lorazepam is a 1,4-benzodiazepine, and is chemically known as a 7-chloro-5-(o-chlorophenyl)-1,3-dihydro-3-hydroxy- 2H-1,4-benzodiazepine-2-one. TRANQIPAM-2,5 mg tablets contain TARTRAZINE. PHARMACOLOGICAL CLASSIFICATION: A 2.6 Tranquillizers. PHARMACOLOGICAL ACTION: TRANQIPAM (lorazepam) is a benzodiazepine and has anxiolytic properties. Benzodiazepines presumably exert their effects by binding to specific receptors at several sites within the central nervous system, by potentiating the effects of synaptic or presynaptic inhibition mediated by gamma-aminobutyric acid. TRANQIPAM (lorazepam) is readily absorbed when given orally. Peak plasma concentrations occur approximately 2 hours following administration. The half-life of unconjugated TRANQIPAM (lorazepam) in human plasma is approximately 12 - 16 hours. TRANQIPAM (lorazepam) is about 90% bound to plasma proteins. Conjugation with glucuronic acid to form the inactive glucuronide of TRANQIPAM (lorazepam) is the major metabolic pathway. Seventy to seventy five percent of the dose is excreted as the glucuronide in the urine. Metabolism is only subject to glucoronidation and is not linked to the action of the cytochrome P450 enzyme system. The plasma levels of TRANQIPAM (lorazepam) are proportional to the dose given. INDICATIONS: TRANQIPAM (lorazepam) is indicated for: 1. Anxiety disturbances or anxiety states: a) general anxiety disturbances b) panic disturbances c) phobic a Perskaitykite visą dokumentą